Health Affairs, 23, no. 1 (2004): 227-236
doi: 10.1377/hlthaff.23.1.227
© 2004 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (18)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kamal-Bahl, S.
* Articles by Briesacher, B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kamal-Bahl, S.
* Articles by Briesacher, B.
Related Collections
* Pharmaceuticals
* Health Spending

DataWatch

How Do Incentive-Based Formularies Influence Drug Selection And Spending For Hypertension?

Sachin Kamal-Bahl and Becky Briesacher

This study examined the association between incentive-based formularies and antihypertensive drug selection and spending. We compared the use of drugs from five drug classes by the number of tiers and copayment differentials. We found that raising copayments within a single-tier formulary system had a relatively modest impact on use of antihypertensives, compared with raising them in multi-tier systems. Likelihood of using ACE inhibitors and angiotensin II receptor blockers was lower among two-tier plans with generic/brand differentials of $10 relative to flat-copayment plans. Incentive formularies were associated with lower total antihypertensive spending by plans, but enrollees paid more out of pocket.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
CLIN PEDIATRHome page
E. Y. Yoon, G. L. Freed, M. M. Davis, and S. J. Clark
Formulary Coverage for Lipid-Lowering Drugs Recommended for Children
Clinical Pediatrics, July 1, 2009; 48(6): 609 - 613.
[Abstract] [PDF]


Home page
JAMAHome page
D. P. Goldman, G. F. Joyce, and Y. Zheng
Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health
JAMA, July 4, 2007; 298(1): 61 - 69.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
H. A. Huskamp, P. A. Deverka, A. M. Epstein, R. S. Epstein, K. A. McGuigan, A. C. Muriel, and R. G. Frank
Impact of 3-Tier Formularies on Drug Treatment of Attention-Deficit/Hyperactivity Disorder in Children
Arch Gen Psychiatry, April 1, 2005; 62(4): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
P. P Gleason, B. W Gunderson, and K. R Gericke
Are Incentive-Based Formularies Inversely Associated with Drug Utilization in Managed Care?
Ann. Pharmacother., February 1, 2005; 39(2): 339 - 345.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
F. T. Shaya, S. Blume, and C. D. Mullins
Prescription Drug Spending Trends For The Privately Insured In Maryland, 2000-2001
Health Aff., September 1, 2004; 23(5): 226 - 232.
[Abstract] [Full Text] [PDF]